Several TIM‐3 inhibitors, such as TQB2618, bc3402, and cobolimab, are undergoing clinical trials in combination with PD‐1/PD‐L1 inhibitors for the treatment of advanced squamous cell carcinoma of the head and neck, liver cancer, non‐small cell lung cancer, and melanoma, with studies progressing at various stages. Here, PDCD1 is linked to lung cancer.